Lausanne, Switzerland and Boston, MA, USA – February 8, 2021: SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC).
The collaboration with the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón — GECP), a Spanish cooperative group for the research on lung cancer, is to show the potential of SOPHiA Radiomics — a groundbreaking application that analyzes medical images for research use — put to use in an additional retrospective analysis of the data from the phase 2 NADIM clinical trial (NCT03081689) (the NADIM trial).
The NADIM trial, funded by Bristol-Myers Squibb and part of the European Union’s Horizon 2020 research and innovation program, aimed to assess the antitumor activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. The important results recently published in The Lancet Oncology supported the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC. This very aggressive type of cancer is unfortunately terminal in most patients with locally advanced staged disease; these results could therefore support a change of perception of locally advanced lung cancer as a potentially lethal disease to one that is curable.
Additional data are expected to be generated through the analysis of the radiology images of NADIM patients through the SOPHiA Radiomics Platform. These data will then be combined with clinical, biological, and genomics data, and multimodal machine learning models will be developed to predict response to neoadjuvant treatment, using baseline and pre-surgery data. The predictive analysis will also aim to stratify patient cohorts with regard to progression-free and overall survival.
“We are very happy to collaborate in this innovative and revolutionary project that opens the door to a new precision medicine. Certainly, this partnership will improve the knowledge relating to the treatment for this group of patients and will allow to approach the best prospects for curing early-stage non-small cell lung cancer (NSCLC)”, said Dr. Mariano Provencio, Head of the Medical Oncology Department at Puerta de Hierro University Hospital in Madrid and lead investigator of the NADIM trial.
“We are very excited to apply our radiomics and multimodal analytics capabilities to such an important clinical question,” said Prof. Thierry Colin, Vice-President of Radiomics Research at SOPHiA GENETICS. “In the Spanish Lung Cancer Group, we have found visionary partners that clearly see the promise of next-generation health data such as radiomics being married with tech-enabled solutions in artificial intelligence to generate entirely novel clinical insights for the benefit of oncology patients.”
“Unlocking the synergistic potential of multimodal health data through artificial intelligence holds revolutionary promise for the future of personalized medicine in oncology and many other health conditions. We are inspired by the potential to positively impact on patients by supporting their care providers in predicting the best course of treatment,” said Dr. Philippe Menu, Chief Medical Officer at SOPHiA GENETICS.
The NADIM trial involved 18 centers from the Spanish Lung Cancer Network that will contribute their data to the joint project.
Results from the additional analysis of NADIM trial data are expected to be available later this year.